Home/Filings/4/0001415889-25-005908
4//SEC Filing

Venrock Healthcare Capital Partners III, L.P. 4

Accession 0001415889-25-005908

CIK 0000907654other

Filed

Feb 26, 7:00 PM ET

Accepted

Feb 27, 6:42 PM ET

Size

25.8 KB

Accession

0001415889-25-005908

Insider Transaction Report

Form 4
Period: 2025-02-10
Transactions
  • Purchase

    Common Stock

    2025-02-11$10.95/sh+9,593$105,0434,035,713 total(indirect: By Funds)
  • Purchase

    Common Stock

    2025-02-10$10.90/sh+574$6,2574,026,120 total(indirect: By Funds)
  • Purchase

    Common Stock

    2025-02-12$11.86/sh+8,971$106,3964,044,684 total(indirect: By Funds)
  • Purchase

    Common Stock

    2025-02-13$11.63/sh+14,950$173,8694,059,634 total(indirect: By Funds)
  • Purchase

    Common Stock

    2025-02-14$11.44/sh+88,794$1,015,8034,148,428 total(indirect: By Funds)
Transactions
  • Purchase

    Common Stock

    2025-02-10$10.90/sh+574$6,2574,026,120 total(indirect: By Funds)
  • Purchase

    Common Stock

    2025-02-11$10.95/sh+9,593$105,0434,035,713 total(indirect: By Funds)
  • Purchase

    Common Stock

    2025-02-14$11.44/sh+88,794$1,015,8034,148,428 total(indirect: By Funds)
  • Purchase

    Common Stock

    2025-02-12$11.86/sh+8,971$106,3964,044,684 total(indirect: By Funds)
  • Purchase

    Common Stock

    2025-02-13$11.63/sh+14,950$173,8694,059,634 total(indirect: By Funds)
Transactions
  • Purchase

    Common Stock

    2025-02-10$10.90/sh+574$6,2574,026,120 total(indirect: By Funds)
  • Purchase

    Common Stock

    2025-02-12$11.86/sh+8,971$106,3964,044,684 total(indirect: By Funds)
  • Purchase

    Common Stock

    2025-02-11$10.95/sh+9,593$105,0434,035,713 total(indirect: By Funds)
  • Purchase

    Common Stock

    2025-02-13$11.63/sh+14,950$173,8694,059,634 total(indirect: By Funds)
  • Purchase

    Common Stock

    2025-02-14$11.44/sh+88,794$1,015,8034,148,428 total(indirect: By Funds)
Transactions
  • Purchase

    Common Stock

    2025-02-10$10.90/sh+574$6,2574,026,120 total(indirect: By Funds)
  • Purchase

    Common Stock

    2025-02-11$10.95/sh+9,593$105,0434,035,713 total(indirect: By Funds)
  • Purchase

    Common Stock

    2025-02-12$11.86/sh+8,971$106,3964,044,684 total(indirect: By Funds)
  • Purchase

    Common Stock

    2025-02-13$11.63/sh+14,950$173,8694,059,634 total(indirect: By Funds)
  • Purchase

    Common Stock

    2025-02-14$11.44/sh+88,794$1,015,8034,148,428 total(indirect: By Funds)
Transactions
  • Purchase

    Common Stock

    2025-02-12$11.86/sh+8,971$106,3964,044,684 total(indirect: By Funds)
  • Purchase

    Common Stock

    2025-02-13$11.63/sh+14,950$173,8694,059,634 total(indirect: By Funds)
  • Purchase

    Common Stock

    2025-02-14$11.44/sh+88,794$1,015,8034,148,428 total(indirect: By Funds)
  • Purchase

    Common Stock

    2025-02-10$10.90/sh+574$6,2574,026,120 total(indirect: By Funds)
  • Purchase

    Common Stock

    2025-02-11$10.95/sh+9,593$105,0434,035,713 total(indirect: By Funds)
Koh Bong Y
10% Owner
Transactions
  • Purchase

    Common Stock

    2025-02-10$10.90/sh+574$6,2574,026,120 total(indirect: By Funds)
  • Purchase

    Common Stock

    2025-02-11$10.95/sh+9,593$105,0434,035,713 total(indirect: By Funds)
  • Purchase

    Common Stock

    2025-02-12$11.86/sh+8,971$106,3964,044,684 total(indirect: By Funds)
  • Purchase

    Common Stock

    2025-02-13$11.63/sh+14,950$173,8694,059,634 total(indirect: By Funds)
  • Purchase

    Common Stock

    2025-02-14$11.44/sh+88,794$1,015,8034,148,428 total(indirect: By Funds)
Shah Nimish P
10% Owner
Transactions
  • Purchase

    Common Stock

    2025-02-10$10.90/sh+574$6,2574,026,120 total(indirect: By Funds)
  • Purchase

    Common Stock

    2025-02-11$10.95/sh+9,593$105,0434,035,713 total(indirect: By Funds)
  • Purchase

    Common Stock

    2025-02-13$11.63/sh+14,950$173,8694,059,634 total(indirect: By Funds)
  • Purchase

    Common Stock

    2025-02-12$11.86/sh+8,971$106,3964,044,684 total(indirect: By Funds)
  • Purchase

    Common Stock

    2025-02-14$11.44/sh+88,794$1,015,8034,148,428 total(indirect: By Funds)
Footnotes (11)
  • [F1]The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $10.88 to $11.00 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote.
  • [F10]The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $11.17 to $11.45 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote.
  • [F11]Consists of (i) 856,747 shares held by VHCP3; (ii) 85,816 shares held by VHCP Co-3; and (iii) 3,205,865 shares held by VHCP EG.
  • [F2]Consists of (i) 835,614 shares held by VHCP3; (ii) 83,701 shares held by VHCP Co-3; and (iii) 3,106,805 shares held by VHCP EG.
  • [F3]VHCP Management III, LLC ("VHCPM3") is the general partner of VHCP3 and the manager of VHCP Co-3 and may be deemed to beneficially own these securities. VHCP Management EG, LLC ("VHCPMEG") is the general partner of VHCPEG and may be deemed to beneficially own these securities. Bong Koh and Nimish Shah are the voting members of VHCPM3 and VHCPMEG and may be deemed to beneficially own these securities. Each of VHCPM3, VHCPMEG and Messrs. Koh and Shah expressly disclaims beneficial ownership over these securities except to the extent of its or his indirect pecuniary interest therein.
  • [F4]The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $10.86 to $11.00 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote.
  • [F5]Consists of (i) 837,271 shares held by VHCP3; (ii) 83,867 shares held by VHCP Co-3; and (iii) 3,114,575 shares held by VHCP EG.
  • [F6]The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $11.25 to $12.00 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote.
  • [F7]Consists of (i) 838,821 shares held by VHCP3; (ii) 84,022 shares held by VHCP Co-3; and (iii) 3,121,841 shares held by VHCP EG.
  • [F8]The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $11.31 to $11.74 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote.
  • [F9]Consists of (i) 841,404 shares held by VHCP3; (ii) 84,280 shares held by VHCP Co-3; and (iii) 3,133,950 shares held by VHCP EG.

Issuer

Oruka Therapeutics, Inc.

CIK 0000907654

Entity typeother
IncorporatedDE

Related Parties

1
  • filerCIK 0001738048

Filing Metadata

Form type
4
Filed
Feb 26, 7:00 PM ET
Accepted
Feb 27, 6:42 PM ET
Size
25.8 KB